retatrutide phase 2 trial type 2 diabetes results 2024 The Effect of on Kidney Parameters in Participants With Mellitus and/or Obesity Retatrutide Results: 28.3% Weight Loss
Description
Having depression is not necessarily a contraindication to GLP-1 treatment, but it requires careful consideration and monitoring
A heavier subgroup continued through 104 weeks, with both groups losing about 30% of baseline weight
These medications slow gastric emptying, meaning food remains in the stomach longer before moving into the small intestine
In high-fat-fed rats, [dA(2)]GLP-1/GcG reduced body weight nonfasting plasma glucose, and boosted circulating plasma insulin concentrations when given twice daily for 21 days
Cagrilintide offers a focused, amylin-based strategy with milder side effects and strong combination therapy potential
GLP-1 receptor agonists (GLP-1 RAs) mimic glucagon-like peptide-1, a hormone released from the gut after eating
